Shares of EyePoint dropped steeply after the company disclosed that a pivotal trial of its lead drug candidate in wet age-related macular degeneration, commonly abbreviated as wet AMD, did not succeed. Headlines covering the move described the sell-off as a collapse, reflecting how heavily the stock had been tied to the program.
The study was a late-stage test in which the experimental therapy was measured against Eylea, the established treatment for the eye condition. Wire reports characterized the result as a setback for the company's flagship asset, and the outcome was the immediate driver of the share price decline.
Alongside the trial news, EyePoint announced a restructuring that would remove 53% of its workforce. The reporting reviewed by FXMARE links the headcount reduction directly to the failed study, indicating the company is resizing its operations after the loss of its main near-term prospect.
The sources supplied do not detail the precise size of the share price drop, the specific trial endpoints that were missed, or how the company plans to use its remaining resources. Those details are therefore not covered here, and readers should consult the company's own disclosures for the full data set.
The episode illustrates the binary nature of late-stage drug development for small and mid-sized biotechnology firms, where a single pivotal readout can reshape a company's valuation and staffing. Wet AMD is a field in which Eylea is the benchmark, so a challenger's failure to show adequate results against it carries particular weight for the developer involved.